J S Quirt1, S Nanji2, X Wei1, J A Flemming3, C M Booth4. 1. Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute. 2. The departments of Oncology, Queen's University, Kingston, ON.; Surgery, Queen's University, Kingston, ON. 3. Medicine, Queen's University, Kingston, ON.; Public Health Sciences, Queen's University, Kingston, ON. 4. Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute; The departments of Oncology, Queen's University, Kingston, ON.; Medicine, Queen's University, Kingston, ON.; Public Health Sciences, Queen's University, Kingston, ON.
Abstract
INTRODUCTION: The incidence of colon cancer varies by sex. Whether women and men show differences in extent of disease, treatment, and outcomes is not well described. We used a large population-based cohort to evaluate sex differences in colon cancer. METHODS: Using the Ontario Cancer Registry, all cases of colon cancer treated with surgery in Ontario during 2002-2008 were identified. Electronic records of treatment identified use of surgery and adjuvant chemotherapy. Pathology reports for a random 25% sample of all cases were obtained, and disease characteristics, treatment, and outcomes in women and men were compared. A Cox proportional hazards model was used to identify factors associated with overall (os) and cancer-specific survival (css). RESULTS: The study population included 7249 patients who underwent resection of colon cancer; 49% (n = 3556) were women. Stage of disease and histologic grade did not vary by sex. Compared with men, women were more likely to have right-sided disease (55% vs. 44%, p ≤ 0.001). Surgical procedure and lymph node yield did not differ by sex. Adjuvant chemotherapy was delivered to 18% of patients with stage ii and 64% of patients with stage iii disease; when adjusted for patient- and disease-related factors, use of adjuvant chemotherapy was similar for women and men [relative risk: 0.99; 95% confidence interval (ci): 0.94 to 1.03]. Adjusted analyses demonstrated that os [hazard ratio (hr): 0.80; 95% ci: 0.75 to 0.86] and css (hr: 0.82; 95% ci: 0.76 to 0.90) were superior for women compared with men. CONCLUSIONS: Long-term survival after colon cancer is significantly better for women than for men, which is not explained by any substantial differences in extent of disease or treatment delivered.
INTRODUCTION: The incidence of colon cancer varies by sex. Whether women and men show differences in extent of disease, treatment, and outcomes is not well described. We used a large population-based cohort to evaluate sex differences in colon cancer. METHODS: Using the Ontario Cancer Registry, all cases of colon cancer treated with surgery in Ontario during 2002-2008 were identified. Electronic records of treatment identified use of surgery and adjuvant chemotherapy. Pathology reports for a random 25% sample of all cases were obtained, and disease characteristics, treatment, and outcomes in women and men were compared. A Cox proportional hazards model was used to identify factors associated with overall (os) and cancer-specific survival (css). RESULTS: The study population included 7249 patients who underwent resection of colon cancer; 49% (n = 3556) were women. Stage of disease and histologic grade did not vary by sex. Compared with men, women were more likely to have right-sided disease (55% vs. 44%, p ≤ 0.001). Surgical procedure and lymph node yield did not differ by sex. Adjuvant chemotherapy was delivered to 18% of patients with stage ii and 64% of patients with stage iii disease; when adjusted for patient- and disease-related factors, use of adjuvant chemotherapy was similar for women and men [relative risk: 0.99; 95% confidence interval (ci): 0.94 to 1.03]. Adjusted analyses demonstrated that os [hazard ratio (hr): 0.80; 95% ci: 0.75 to 0.86] and css (hr: 0.82; 95% ci: 0.76 to 0.90) were superior for women compared with men. CONCLUSIONS: Long-term survival after colon cancer is significantly better for women than for men, which is not explained by any substantial differences in extent of disease or treatment delivered.
Entities:
Keywords:
Colon cancer; chemotherapy; outcomes; sex effects; surgery
Authors: C Cao; T D Yan; M Deraco; D Elias; O Glehen; E A Levine; B J Moran; D L Morris; T C Chua; P Piso; P H Sugarbaker Journal: Ann Oncol Date: 2011-11-04 Impact factor: 32.976
Authors: Fotios Loupakis; Dongyun Yang; Linda Yau; Shibao Feng; Chiara Cremolini; Wu Zhang; Martin K H Maus; Carlotta Antoniotti; Christiane Langer; Stefan J Scherer; Thomas Müller; Herbert I Hurwitz; Leonard Saltz; Alfredo Falcone; Heinz-Josef Lenz Journal: J Natl Cancer Inst Date: 2015-02-24 Impact factor: 13.506
Authors: Rowan T Chlebowski; Jean Wactawski-Wende; Cheryl Ritenbaugh; F Allan Hubbell; Joao Ascensao; Rebecca J Rodabough; Carol A Rosenberg; Victoria M Taylor; Randall Harris; Chu Chen; Lucile L Adams-Campbell; Emily White Journal: N Engl J Med Date: 2004-03-04 Impact factor: 91.245
Authors: Barry J Laird; Stein Kaasa; Donald C McMillan; Marie T Fallon; Marianne J Hjermstad; Peter Fayers; Pal Klepstad Journal: Clin Cancer Res Date: 2013-08-12 Impact factor: 12.531
Authors: Camila M Lopes-Ramos; Marieke L Kuijjer; Shuji Ogino; Charles S Fuchs; Dawn L DeMeo; Kimberly Glass; John Quackenbush Journal: Cancer Res Date: 2018-10-01 Impact factor: 12.701
Authors: Eva Braunwarth; Benedikt Rumpf; Florian Primavesi; David Pereyra; Margarethe Hochleitner; Georg Göbel; Silvia Gasteiger; Philipp Gehwolf; Dietmar Öfner; Patrick Starlinger; Stefan Stättner Journal: PLoS One Date: 2020-12-14 Impact factor: 3.240
Authors: Anita L Ray; Robert A Nofchissey; Maaz A Khan; Megan A Reidy; Megan R Lerner; Xiangyan Wu; Shaoxuan Guo; Spencer L Hill; Nathaniel Weygant; Sarah F Adams; Eliseo F Castillo; William L Berry; Michael B Stout; Katherine T Morris Journal: Br J Cancer Date: 2020-05-26 Impact factor: 7.640